menu
    • menu
    [{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Butylated Hydroxyanisole","moa":"Free radical","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Carmell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Butylated Hydroxyanisole","moa":"Free radical","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Carmell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Butylated Hydroxyanisole","moa":"Free radical","graph1":"Podiatry","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Butylated Hydroxyanisole

    Menu

    Butylated Hydroxyanisole

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Carmell Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Carmell Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Butylated Hydroxyanisole

                            Therapeutic Area : Podiatry

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bone Healing Accelerant (BHA) Versus Autologous Bone Grafting (ABG) for Hindfoot or Ankle Arthrodesis

                            Details : Butylated Hydroxyanisole is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Foot Deformities.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 14, 2024

                            Lead Product(s) : Butylated Hydroxyanisole

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Carmell Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Carmell Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Butylated Hydroxyanisole

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Multiregion BHA in Open Tibia Fractures

                            Details : Butylated Hydroxyanisole is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Tibial Fractures.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 14, 2019

                            Lead Product(s) : Butylated Hydroxyanisole

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Carmell Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Carmell Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Butylated Hydroxyanisole

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bone Healing Accelerant Versus Standard of Care for Open Tibia Fractures

                            Details : Butylated Hydroxyanisole is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tibial Fractures.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 01, 2019

                            Lead Product(s) : Butylated Hydroxyanisole

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth